

RECEIVED

OCT 02 2001

TECH CENTER 1600/2909

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Application Number	09/715,340	
		Filing Date	April 13, 2001	
		First Named Inventor	Kappes	
		Group Art Unit	1648	
		Examiner Name		
Sheet <b>O I P E I</b>	of	3	Attorney Docket Number	5854-2 (044276/209251)

U. S. PATENT DOCUMENTS						
Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant Of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear
		Number	Kind Code (if known)			
<b>STF</b>	1	5,026,635		Du Pont Merck Pharmaceutical		Whole Document
	2	5,110,906		The Trustees of Columbia University, in the City of New York, New York		Whole Document
	3	5,126,433		The Trustees of Columbia University in the City of the City of New York, New York		Whole Document
	4	5,422,274		The Trustees of Columbia University of the City of New York, New York.		Whole Document
	5	5,670,324		The Regents of the University of California		Whole Document
	6	5,811,282		The United States of America as represented by the Secretary of the Department of Health and Human Services		Whole Document
	7	5,817,767		Progenics Pharmaceuticals, Inc.		Whole Document
	8	5,837,464		ViroLogic, Inc.		Whole Document
	9	6,025,154		Human Genome Sciences, Inc.		Whole Document

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
<b>STF</b>	10	WO	96/19495	A1	Duke University	06-27-1996	Whole Document	
<b>STF</b>	11	WO	97/28258	A1	The National Institutes of Health	08-07-1997	Whole Document	

Examiner Signature		Date Considered	8/1/02
-----------------------	---	--------------------	--------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number.

<sup>1</sup> See attached Kinds of U.S. Patent Documents.

<sup>1</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>1</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>1</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.

<sup>1</sup> Applicant is to place an "X" here if English language Translation is attached.

RECEIVED

OCT 02 2001

TECH CENTER 1600/2900

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Application Number	09/719,340		
		Filing Date	April 13, 2001		
		First Named Inventor	Kappes		
		Group Art Unit	1648		
		Examiner Name			
Sheet	3	of	3	Attorney Docket Number	5854-2 (044276/209251)

FOREIGN PATENT DOCUMENTS							
Examiner Initials	Cite No.	Foreign Patent Document	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
SHF	12	WO	00/65356	A1	Bio-Tech Imaging, Inc.	11-02-2000	Whole Document

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
SHF	13	CHACKERIAN, B., <i>et al.</i> , "Human Immunodeficiency Virus Type 1 Coreceptors Participate in Postentry States in the Virus Replication Cycle and Function in Simian Immunodeficiency Virus Infection," <i>Journal of Virology</i> , May 1997, pp. 3932-3939, Vol. 71, American Society for Microbiology, USA.	
	14	JAMES, J., "T-20 and Trimeris", <i>Aids Treatment News</i> , April 1998, pp. 1-6.	
	15	KILBY, M., <i>et al.</i> , "Potent Suppression of HIV-1 Replication in Humans by T-20, a Peptide Inhibitor of gp41-Mediated Virus Entry," <i>Nature Medicine</i> , 1998, pp.1302-1307, Vol.4 (11).	
	16	KUHMANN, S., <i>et al.</i> , "Polymorphisms in CCR5 Genes of African Green Monkeys and Mice Implicate Specific Amino Acids in Infections by Simian and Human Immunodeficiency Viruses," <i>Journal of Virology</i> , November 1997, Vol. 71(11), American Society for Microbiology.	
	17	MADDON, P., <i>et al.</i> , "The Isolation and Nucleotide Sequence of a cDNA Encoding the T Cell Surface Protein T4: A New Member of the Immunoglobulin Gene Family, <i>Cell</i> , 1985, pp. 93-104, Vol:42, College of Physicians and Surgeons, New York.	
	18	PLATT, E., <i>et al.</i> , "Effects of CCR5 and CD4 Cell Surface Concentrations on Infections by Macrophagetropic Isolates of Human Immunodeficiency Virus Type 1," <i>Journal of Virology</i> , 1998, pp. 2855-2864, American Society for Microbiology.	
SHF	19	RAPORT, C., <i>et al.</i> , "Molecular Cloning and Functional Characterization of a Novel Human CC Chemokine receptor (CCR5) for RANTES, MIP-1 $\beta$ , and MIP-1 $\alpha$ ," <i>Journal of Biological Chemistry</i> , 1996, pp. 17161-17166, Vol. 271(29), The American Society for Biochemistry and Molecular Biology, Inc. USA.	
	20	RIMSKY, L., <i>et al.</i> , "Determinants of Human Immunodeficiency Virus Type 1 Resistance to gp41-Derived Inhibitory Peptides," <i>Journal of Virology</i> , 1998, pp. 986-993, Vol. 72 (2), American Society for Microbiology.	

Examiner Signature	<i>SHF</i>	Date Considered	8/2/2
--------------------	------------	-----------------	-------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number.

<sup>1</sup> See attached Kinds of U.S. Patent Documents.

<sup>1</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>1</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.


<sup>1</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.

<sup>1</sup> Applicant is to place an "X" here if English language Translation is attached.

RECEIVED

OCT 1 0 2 2001  
TECH CENTER 1600/2900

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Application Number	09/719,340
				Filing Date	April 13, 2001
				First Named Inventor	Kappes
				Group Art Unit	1648
				Examiner Name	
Sheet	3	of	3	Attorney Docket Number	5854-2 (044276/209251)

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	21	BLACK, R., <i>et al.</i> , "Comparison of Methodologies for Detecting HIV Resistance," Int. Conf. AIDS, 1991, Abstract No. W.A. 1078.	
	22	JAPOUR, L., <i>et al.</i> , "A Direct Test for Zidovudine (ZDV) Resistance in Clinical Isolates of HIV," Int. Conf. AIDS, 1993, Abstract No. PO-B26-2048.	
	23	JACKSON, C., <i>et al.</i> , "Stavudine Sensitivities in Clinical HIV Isolates Obtained from a Pediatric Population," American Pediatric Association and Society for Pediatric Research Annual Meeting, May 6-10, 1996, unnumbered abstract.	
	24	WEI, X., <i>et al.</i> , "HIV-1 Selection in Response to Inhibition of Virus Fusion and Entry," Abstract 611	

RTA01/2103984v1

Examiner Signature		Date Considered	8/2/02
--------------------	---	-----------------	--------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number.

<sup>1</sup> See attached Kinds of U.S. Patent Documents.

<sup>1</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>1</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>1</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.

<sup>1</sup> Applicant is to place an "X" here if English language Translation is attached.

RECEIVED

APR 19 2002

TECH CENTER 1609/2900

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

Application Number	09/719,340
Filing Date	April 13, 2001
First Named Inventor	Kappes
Group Art Unit	1648
Examiner Name	
Attorney Docket Number	44276/209251 (5854-2)

(See as many sheets as necessary)

Sheet of 1

APR 16 2002

## U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant Of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear
SH	25	US-5,532,124		Block and Grafstrom	07-02-1996	

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Office Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T

Examiner Signature	<i>Shannon Foley</i>	Date Considered	8/7/02
-----------------------	----------------------	--------------------	--------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number.

<sup>1</sup> See attached Kinds of U.S. Patent Documents.

<sup>1</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>1</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>1</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.

<sup>1</sup> Applicant is to place an "X" here if English language Translation is attached.

Substitute for form 1449A/PTO (Revised 10/2001)  <b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>		<b>Complete if Known</b>			
		Application Number	09/719,340		
		Filing Date	4/13/01		
		First Named Inventor	Kappes		
		Group Art Unit	1648		
Examiner Name	Shanon A. Foley				
Sheet 1 of 1	Attorney Docket Number		44276/209251 (5854-2)		
<b>U. S. PATENT DOCUMENTS</b>					
Examiner Initials*	Cite No.	Document Number Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear
SE	26	US-2002/0037281	03/28/2002	DAVIDSON <i>et al.</i>	
SE	27	US-2002/0037498	03/28/2002	HALLOWITZ <i>et al.</i>	
<b>FOREIGN PATENT DOCUMENTS</b>					
Examiner Initials	Cite No.	Foreign Patent Document Country Code - Number Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
<b>OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			

Examiner Signature		Date Considered	8/7/02
--------------------	---	-----------------	--------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RTA01/2118700v1

Substitute for form 1449A/PTO (Revised 10/2001)

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT**  
(Use as many sheets as necessary)

Sheet 1 of 1

**Complete if Known**

Application Number 09/719,340

Filing Date 4/13/01

First Named Inventor Kappes

Group Art Unit 1648

Examiner Name Shanon A. Fley

Attorney Docket Number 44276/209251 (5854-2)

**RECEIVED**  
JUL 11 2002  
TECH CENTER 1600/2900

### U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document Number Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear

### FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code - Number Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
SFF	28	WO 98/00535	01/08/1998	DANA-FARBER CANCER INSTITUTE		
SFF	29	WO 99/23107	05/14/1999	MAXYGEN, INCORPORATED		

### OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
SFF	30	DEICHMANN, M. <i>et al.</i> , "Expression of the Human Immunodeficiency Virus Type-1 Coreceptors CXCR-4 (fusin, LESTR) and CKR-5 in CD34+ Hematopoietic Progenitor Cells," <i>Blood</i> , 1997, pp. 3522-3528, Vol. 89(10).	
	31	D'SOUZA, M. and HARDEN, V., "Chemokines and HIV-1 Second Receptors," <i>Nature Medicine</i> , 1996, pp. 1293-1300, Vol. 2(12).	
	32	HASLER, J., <i>et al.</i> , "A Rapid, Quantitative Bioassay Based on the Human Immunodeficiency Virus Trans-Activator," <i>Aids Research and Human Retroviruses</i> , 1989, pp. 507-516, Vol. 5(5).	
	33	MOORE, J., <i>et al.</i> , "Co-receptors for HIV-1 Entry," <i>Current Opinion in Immunology</i> , 1997, pp. 551-562, Vol. 9(4).	
SFF	34	ZELLA, D., <i>et al.</i> , "Interferon-γ Increases Expression of Chemokine Receptors CCR1, CCR3, and CCR5, But Not CXCR4 in Monocytoid U937 Cells," <i>Blood</i> , 1998, pp. 4444-4450, Vol. 91(12).	

Examiner Signature		Date Considered	8/7/02
--------------------	---	-----------------	--------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.